31/08/2026 MT027 secures US FDA Fast Track designation for recurrent Glioblastoma FDA clears IDEAYA’s IDE849 Phase 3 path in ES-SCLC In Phase 3 HERIZON-GEA-01 trial, ZIIHERA + chemotherapy demonstrated a statistically significant improvement in OS vs trastuzumab + chemotherapy, meeting the primary endpoint ORPATHYS + TAGRISSO® demonstrated significant PFS benefit with early OS signal in first-line EGFRm NSCLC with MET overexpression Karyopharm files sNDA for selinexor + ruxol

25/08/2026 US FDA approves zanidatamab combination therapy in HER2+ GEA US FDA approves zanidatamab combination therapy in HER2+ GEA (Ref) The US FDA has approved Jazz, BeOne and Zymeworks' Ziihera (zanidatamab-hrii; bispecific HER2-directed antibody) with and without BeOne's tislelizumab (anti-PD-1) + chemotherapy for first-line treatment of HER2+ advanced gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status Approval was supported by Phase 3 HERIZON-GEA-01 trial

27/04/2026 Zanidatamab combinations receive the FDA priority review status for HER2+ GEA; PDUFA date of Aug'26 set Tovecimig + paclitaxel significantly improved PFS and ORR in biliary tract cancer; sBLA submission planned FDA Grants Breakthrough Therapy Designation to TERN-701 in Chronic Myeloid Leukemia Relay Therapeutics Advances PI3Kα/CDK4 Triplet Toward Frontline Breast Cancer Phase 3 Trial Zanidatamab combinations receive the FDA priority review status for HER2+ GEA; PDU

01/07/2025 HanchorBio and Henlius signed a ~$200M licensing deal for HanchorBio's HCB101 (Ref) HanchorBio and Shanghai Henlius Biotech signed an out-licensing agreement which granted Henlius the exclusive development and commercialization rights to HanchorBio's HCB101 (SIRPα-IgG4 Fc fusion protein) across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA) Under the